ReviewInfection & chemotherapy2023
Diagnosis and Treatment of Invasive Mold Diseases.
Review in Infection & chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Geographically structured genotypes and resistance clustering in Aspergillus fumigatus.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Article
- Advancing mold identification in the routine laboratory, performance of smartphone-based imaging and a newly developed convolutional neural network.Microbiology spectrum · 2026Article
- Fatal Cutaneous Mucormycosis Initially Misdiagnosed as Necrotizing Fasciitis in an Uncontrolled Diabetic Patient: A Case Report Highlighting Diagnostic Delay.International medical case reports journal · 2026Article
- Management of mould pneumonia in resource-limited settings in Asia: A Delphi-based consensus statement by the Asia Fungal Working Group.Medical mycology · 2025Article
- Pathologically Confirmed Dual Coronavirus Disease 2019-Associated Tracheobronchial Aspergillosis and Pulmonary Mucormycosis in a Non-Endemic Region: A Case Report.Journal of clinical medicine · 2025Article
- Observational
- Article
- Rapid Differentiation of False Positives of Galactomannan Related to Contaminated Intravenous Fluids via a Pharmacokinetics Model and Innovative Web-Based Tool.Open forum infectious diseases · 2025Article
- Evaluation of the combined efficacy of inhibitors of heat shock protein 90 and calcineurin with commonly used antifungals againstCurrent medical mycology · 2025Article
- Successful treatment ofWorld journal of clinical cases · 2024Article
- Clinical Implementation ofJournal of fungi (Basel, Switzerland) · 2023Article
- Clinical Characteristics of Nocardiosis: a Multicenter Retrospective Study in Korea.Infection & chemotherapy · 2023Article
- Clinical impact of microbial cell-free DNA next-generation sequencing for invasive mold infection-a single-center retrospective observational study.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although invasive fungal diseases are relatively less common than superficial diseases, there has been an overall increase in their incidence. Here, I review the epidemiology, diagnosis, and treatment of invasive mold diseases (IMDs) such as aspergillosis, mucormycosis, hyalohyphomycosis, and phaeohyphomycosis. Histopathologic demonstration of tissue invasion by hyphae or recovery of mold by the culture of a specimen obtained by a sterile procedure provides definitive evidence of IMD. If IMD cannot be confirmed through invasive procedures, IMD can be diagnosed through clinical criteria such as the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Instituteof Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions. For initial primary therapy of invasive aspergillosis, voriconazole or isavuconazole is recommended and lipid formulations of amphotericin B are useful primary alternatives. Echinocandins are representative antifungal agents for salvage therapy. Treatment of invasive mucormycosis involves a combination of urgent surgical debridement of involved tissues and antifungal therapy. Lipid formulations of amphotericin B are the drug of choice for initial therapy. Isavuconazole or posaconazole can be used as salvage or step-down therapy. IMDs other than aspergillosis and mucormycosis include hyalohyphomycosis and phaeohyphomycosis, for which there is no standard therapy and the treatment depends on the clinical disease and status of the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.